Cart
sales@molnova.com
Orbifloxacin
CAS No. 113617-63-3
Orbifloxacin( CP 104,354 )
Catalog No. M10479 CAS No. 113617-63-3
Orbifloxacin is a synthetic broad-spectrum fluoroquinolone antibiotic.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | In Stock |
|
| 200MG | 28 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOrbifloxacin
-
NoteResearch use only, not for human use.
-
Brief DescriptionOrbifloxacin is a synthetic broad-spectrum fluoroquinolone antibiotic.
-
DescriptionOrbifloxacin is a synthetic broad-spectrum fluoroquinolone antibiotic.
-
In Vitro——
-
In Vivo——
-
SynonymsCP 104,354
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research AreaInfection
-
Indication——
Chemical Information
-
CAS Number113617-63-3
-
Formula Weight395.38
-
Molecular FormulaC19H20F3N3O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: 0.05 mg/mL (0.12 mM)
-
SMILESO=C(C1=CN(C2CC2)C3=C(C(F)=C(F)C(N4C[C@H](C)N[C@H](C)C4)=C3F)C1=O)O
-
Chemical Name1-Cyclopropyl-7-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-5,6,8-trifluoro-4-oxoquinoline-3-carboxylic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ganière JP, et al. Res Vet Sci. 2004 Aug; 77(1):67-7
molnova catalog
related products
-
FMRF
FMRF is a peptide consisting of 4 amino acid residues.
-
L-822179
L-822179 (α5IA) is a selective inverse agonist for the Α5 subtype of GABAA receptor with higher intrinsic activity at the A5 subtype than other drugs.
-
Remimazolam
Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?
